{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00939068",
      "OrgStudyIdInfo": {
        "OrgStudyId": "H200804"
      },
      "Organization": {
        "OrgFullName": "Southeast University, China",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission",
      "OfficialTitle": "A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2009",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2008"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2010",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 2010",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 13, 2009",
      "StudyFirstSubmitQCDate": "July 13, 2009",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 14, 2009",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 13, 2009",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 14, 2009",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Wei Zhao",
        "ResponsiblePartyOldOrganization": "the Second Hospital of Nanjing, China"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Southeast University, China",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of Telbivudine in pregnancy for the prevention of HBV perinatal transmission in highly viraemic mothers.",
      "DetailedDescription": "In the present study, we evaluated the effect of telbivudine given during the second and third trimesters of pregnancy to highly viremic, HBV DNA-positive mothers on maternal HBV DNA and HBeAg levels prior to delivery and the rate of vertical transmission of HBV to infants who received passive-active immunoprophylaxis. Additionally, we investigated the timing of the administration of telbivudine on reducing the risk of perinatal transmission and the safety of telbivudine during pregnancy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Hepatitis B, Gestation"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Chronic hepatitis B, Telbivudine, Intrauterine transmission"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 4"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "180",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Telbivudine",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Telbivudine"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: engineered HB vaccine"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Telbivudine",
            "InterventionDescription": "Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Telbivudine"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "telbivudine treatment"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "engineered HB vaccine",
            "InterventionDescription": "All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Control"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "control group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "the intrauterine transmission rate;vertical transmission rate (intrauterine and delivery)",
            "PrimaryOutcomeTimeFrame": "1 month post partum"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "liver function normalization rate; HBV DNA and HBeAg reduction and negative conversion rate;",
            "SecondaryOutcomeTimeFrame": "1 month post partum"
          },
          {
            "SecondaryOutcomeMeasure": "drug adverse reaction in pregnant women; complications during pregnancy and delivery, gestational age at delivery, the method of delivery, peripartum hemorrhage, the newborn growth and development milestones, Apgar score, newborn deformity prevalence",
            "SecondaryOutcomeTimeFrame": ".1 year after childbirth"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n20-40 years old pregnant woman with gestational age of 20-32 week;\npositive serum HBsAg;\nHBV DNAâ‰¥1.0x106 copies/ml;\n\nExclusion Criteria:\n\nwith previous antiviral treatment;\nwith clinical sign of threatened miscarriage or related treatment in early pregnancy;\npositive serum HAV, HCV, HDV and HEV tests;\nfetus deformity by 3-D ultrasound examination;\non other dugs, such as immune modulators, cytotoxic drugs or steroids;\nhusbands are infected with HBV.",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "MinimumAge": "20 Years",
      "MaximumAge": "40 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Wei Zhao, P.H.D",
            "OverallOfficialAffiliation": "the Second Affiliated Hospital of Southeast University",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "28039902",
            "ReferenceType": "derived",
            "ReferenceCitation": "Han GR, Jiang HX, Wang CM, Ding Y, Wang GJ, Yue X, Zhou L, Zhao W. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat. 2017 Jun;24(6):514-521. doi: 10.1111/jvh.12670. Epub 2017 Feb 14."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006506",
            "ConditionMeshTerm": "Hepatitis A"
          },
          {
            "ConditionMeshId": "D000006509",
            "ConditionMeshTerm": "Hepatitis B"
          },
          {
            "ConditionMeshId": "D000019694",
            "ConditionMeshTerm": "Hepatitis B, Chronic"
          },
          {
            "ConditionMeshId": "D000006505",
            "ConditionMeshTerm": "Hepatitis"
          },
          {
            "ConditionMeshId": "D000006521",
            "ConditionMeshTerm": "Hepatitis, Chronic"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000006525",
            "ConditionAncestorTerm": "Hepatitis, Viral, Human"
          },
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000007239",
            "ConditionAncestorTerm": "Infections"
          },
          {
            "ConditionAncestorId": "D000004769",
            "ConditionAncestorTerm": "Enterovirus Infections"
          },
          {
            "ConditionAncestorId": "D000010850",
            "ConditionAncestorTerm": "Picornaviridae Infections"
          },
          {
            "ConditionAncestorId": "D000012327",
            "ConditionAncestorTerm": "RNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000086982",
            "ConditionAncestorTerm": "Blood-Borne Infections"
          },
          {
            "ConditionAncestorId": "D000003141",
            "ConditionAncestorTerm": "Communicable Diseases"
          },
          {
            "ConditionAncestorId": "D000018347",
            "ConditionAncestorTerm": "Hepadnaviridae Infections"
          },
          {
            "ConditionAncestorId": "D000004266",
            "ConditionAncestorTerm": "DNA Virus Infections"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8747",
            "ConditionBrowseLeafName": "Hepatitis B",
            "ConditionBrowseLeafAsFound": "Hepatitis B",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M20762",
            "ConditionBrowseLeafName": "Hepatitis B, Chronic",
            "ConditionBrowseLeafAsFound": "Chronic Hepatitis B",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8743",
            "ConditionBrowseLeafName": "Hepatitis",
            "ConditionBrowseLeafAsFound": "Hepatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8744",
            "ConditionBrowseLeafName": "Hepatitis A",
            "ConditionBrowseLeafAsFound": "Hepatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8759",
            "ConditionBrowseLeafName": "Hepatitis, Chronic",
            "ConditionBrowseLeafAsFound": "Chronic Hepatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8762",
            "ConditionBrowseLeafName": "Hepatitis, Viral, Human",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7082",
            "ConditionBrowseLeafName": "Enterovirus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12897",
            "ConditionBrowseLeafName": "Picornaviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14301",
            "ConditionBrowseLeafName": "RNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19640",
            "ConditionBrowseLeafName": "Hepadnaviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6594",
            "ConditionBrowseLeafName": "DNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2787",
            "ConditionBrowseLeafName": "Herpes Simiae (B Virus)",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000077712",
            "InterventionMeshTerm": "Telbivudine"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000998",
            "InterventionAncestorTerm": "Antiviral Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          },
          {
            "InterventionAncestorId": "D000019384",
            "InterventionAncestorTerm": "Nucleic Acid Synthesis Inhibitors"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M16512",
            "InterventionBrowseLeafName": "Vaccines",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1879",
            "InterventionBrowseLeafName": "Telbivudine",
            "InterventionBrowseLeafAsFound": "Cyclosporine A",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3466",
            "InterventionBrowseLeafName": "Antiviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}